Lewis H. Titterton, Jr. Purchases 10,738 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. bought 10,738 shares of the stock in a transaction on Friday, June 7th. The shares were acquired at an average cost of $2.52 per share, for a total transaction of $27,059.76. Following the purchase, the director now owns 848,775 shares in the company, valued at $2,138,913. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Anixa Biosciences Price Performance

Anixa Biosciences stock opened at $2.62 on Wednesday. Anixa Biosciences, Inc. has a one year low of $2.21 and a one year high of $5.13. The company’s fifty day moving average price is $2.89 and its two-hundred day moving average price is $3.55. The company has a market capitalization of $83.87 million, a price-to-earnings ratio of -7.08 and a beta of 0.84.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Tuesday, June 4th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. As a group, sell-side analysts anticipate that Anixa Biosciences, Inc. will post -0.44 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright dropped their price target on shares of Anixa Biosciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday.

Institutional Trading of Anixa Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIX. International Assets Investment Management LLC boosted its position in shares of Anixa Biosciences by 274.6% in the fourth quarter. International Assets Investment Management LLC now owns 54,320 shares of the company’s stock valued at $2,110,000 after acquiring an additional 39,820 shares during the period. Simplicity Wealth LLC acquired a new position in shares of Anixa Biosciences in the 1st quarter valued at $44,000. Staley Capital Advisers Inc. bought a new position in Anixa Biosciences during the first quarter worth about $31,000. Finally, Virtu Financial LLC grew its stake in shares of Anixa Biosciences by 47.2% in the 1st quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after purchasing an additional 5,183 shares during the period. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.